Stock GMTX GEMI THER
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

GEMI THER Stock

Equities

GMTX

US36870G1058

Chart GEMI THER

Dynamic Chart

Latest news about GEMI THER

Arix portfolio firm Disc Medicine seals Gemini Therapeutics merger AN
Gemini Therapeutics, Inc.(NasdaqGM:GMTX) dropped from NASDAQ Composite Index CI
Disc Medicine, Inc. completed the acquisition of Gemini Therapeutics, Inc. for approximately $200 million in a reverse merger transaction. CI
Gemini Therapeutics Shares Rise After Disc Medicine Gets FDA Designation DJ
Gemini Therapeutics' Disc Medicine Secures FDA's Orphan Drug Status for Erythropoietic Protoporphyria Treatment MT
Gemini Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Gemini Therapeutics, Inc.(NasdaqGM:GMTX) dropped from S&P Global BMI Index CI
Gemini Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Arix Bioscience To Invest $54 Million To Fund All-stock Disc Medicine, Gemini Therapeutics Merger MT
Gemini Therapeutics Merges With Disc Medicine MT
Disc Medicine, Inc. entered into an agreement to acquire Gemini Therapeutics, Inc. in a reverse merger transaction. CI
Gemini Therapeutics, Inc.(NasdaqGM:GMTX) dropped from Russell 2000 Defensive Index CI
Gemini Therapeutics, Inc.(NasdaqGM:GMTX) dropped from Russell Microcap Growth Index CI
Gemini Therapeutics, Inc.(NasdaqGM:GMTX) dropped from Russell 3000E Value Index CI
Gemini Therapeutics, Inc.(NasdaqGM:GMTX) dropped from Russell 3000 Value Index CI
More news

Analyst Recommendations on GEMI THER

HC Wainwright Downgrades Gemini Therapeutics to Neutral From Buy, Adjusts Price Target to $2 From $5 MT
SVB Leerink Downgrades Gemini Therapeutics to Market Perform from Outperform, Adjusts Price Target to $2 from $10 MT
HC Wainwright Adjusts Price Target on Gemini Therapeutics to $5 From $20, Reiterates Buy Rating MT
Jefferies Downgrades Gemini Therapeutics to Hold From Buy, Adjusts Price Target to $1.50 From $23 MT
SVB Leerink Adjusts Gemini Therapeutics' Price Target to $10 from $15, Keeps Outperform Rating MT
More recommendations

Press releases GEMI THER

DISC MEDICINE, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Amendment or Waiver to Code of Ethics, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K) AQ
GEMINI THERAPEUTICS, INC. /DE : Submission of Matters to a Vote of Security Holders, Other Events (form 8-K) AQ
GEMINI THERAPEUTICS, INC. /DE : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) AQ
Disc Medicine Announces Several Presentations Across Hematology Portfolio at the 64th American Society of Hematology Annual Meeting AQ
GEMINI THERAPEUTICS, INC. /DE : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) AQ
More press releases

News in other languages on GEMI THER

¿Se acerca el criptoinvierno?
More news

Company Profile

Gemini Therapeutics, Inc., formerly FS Development Corp., is a clinical-stage precision medicine company. The Company is principally focused on developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration (AMD). The Company's lead product candidate, GEM103, is a recombinant form of the human complement factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. Its Pipeline of product candidate includes (adeno-associated virus) AAV-CFH, AAV-CFI, AAV-Ab, GEM104 and GEM307. Its AAV-CFH program is complementary to GEM103 program, as AAV-CFH to construct that express GEM103 continuously at a therapeutic level. Its pipeline is designed to develop treatments for genetically subpopulations of patients suffering from dry AMD and linked diseases. The Company do not own or operate manufacturing facilities for the production of clinical or commercial quantities of its product candidates.
Sector
-
More about the company
  1. Stock Market
  2. Equities
  3. GMTX Stock